Erratum: The IL-33/ST2 axis augments effector T-cell responses during acute GVHD (Blood (2015) 125:20 (3183-3192) DOI: 10.1182/blood-2014-10-606830);The IL-33/ST2 axis augments effector T-cell responses during acute GVHD

Blood

Volumn 125, Issue 20, 2015, Pages 3183-3192

  Reichenbach, Dawn K ^a   Schwarze, Vincent ^b   Matta, Benjamin M ^c   Tkachev, Victor ^d   Lieberknecht, Elisabeth ^b   Liu, Quan ^c   Koehn, Brent H ^a   Pfeifer, Dietmar ^b   Taylor, Patricia A ^a   Prinz, Gabriele ^b   Dierbach, Heide ^b   Stickel, Natalie ^b   Beck, Yvonne ^b   Warncke, Max ^e   Junt, Tobias ^e   Schmitt Graeff, Annette ^b   Nakae, Susumu ^f   Follo, Marie ^b   Wertheimer, Tobias ^b   Schwab, Lukas ^b   Devlin, Jason ^g   Watkins, Simon C ^g   Duyster, Justus ^b   Ferrara, James L M ^d   Turnquist, Heth R ^a,c,g   Zeiser, Robert ^b,h   Blazar, Bruce R ^a   more..

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f THE UNIVERSITY OF TOKYO   (Japan)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; BUSULFAN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 33; SUPPRESSION OF TUMORIGENICITY 2 PROTEIN; THIOTEPA; TREOSULFAN; TUMOR NECROSIS FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOREACTIVE T CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LETHALITY; MAJOR CLINICAL STUDY; MOUSE; MYELOABLATIVE CONDITIONING; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN INTERACTION; T LYMPHOCYTE; UPREGULATION; ACUTE DISEASE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; BIOSYNTHESIS; CLUSTER ANALYSIS; DISEASE MODEL; DONOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE; KNOCKOUT MOUSE; METABOLISM; MORTALITY; PATHOLOGY; RADIATION RESPONSE; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; ANIMALS; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-33; INTERLEUKINS; INTESTINES; ISOANTIGENS; MICE; MICE, KNOCKOUT; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84943606387     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-07-728048     Document Type: Erratum

References (76)

1. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538-1549.
2. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104(1):282-287.
3. Moussion C, Ortega N, Girard J-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE. 2008;3(10): e3331.
4. Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol. 2011; 89(3):383-392.
5. Kurowska-Stolarska M, Stolarski B, Kewin P, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009;183(10): 6469-6477.
6. Polumuri SK, Jayakar GG, Shirey KA, et al. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol. 2012;189(1): 50-60.
7. Cayrol C, Girard J-P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009;106(22):9021-9026.
8. Lüthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84-98.
9. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284(29):19420-19426.
10. Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 1993;318(1):83-87.
11. Tominaga S, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun. 1999;264(1): 14-18.
12. Cho K-A, Suh JW, Sohn JH, et al. IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol. 2012;302(4):L429-L440.
13. Duan L, Chen J, Zhang H, et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3+ regulatory T-cell responses in mice. Mol Med. 2012;18(5):753-761.
14. Liu Q, Turnquist HR. Implications for interleukin-33 in solid organ transplantation. Cytokine. 2013; 62(2):183-194.
15. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA. 2007;104(47):18660-18665.
16. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007;179(4):2051-2054.
17. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007;40(3):216-225.
18. Löhning M, Stroehmann A, Coyle AJ, et al. T1/ ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA. 1998;95(12): 6930-6935.
19. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187(5):787-794.
20. Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, et al. IL-33 enhances lipopolysaccharideinduced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol. 2009;183(2):1446-1455.
21. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009;123(5):1047-1054.
22. Turnquist HR, Zhao Z, Rosborough BR, et al. IL-33 expands suppressive CD11b1 Gr-1(int) and regulatory T cells, including ST2L1 Foxp31 cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol. 2011;187(9):4598-4610.
23. Willart MAM, Deswarte K, Pouliot P, et al. Interleukin-1a controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med. 2012;209(8): 1505-1517.
24. Smithgall MD, Comeau MR, Yoon B-RP, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergenreactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20(8):1019-1030.
25. Liew FY, Pitman NI, McInnes IB. Diseaseassociated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10(2): 103-110.
26. Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA. 2010;107(17):8017-8022.
27. Zhou L, Chong MMW, Littman DR. Plasticity of CD41 T cell lineage differentiation. Immunity. 2009;30(5):646-655.
28. Hueber AJ, Alves-Filho JC, Asquith DL, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol. 2011;41(8): 2229-2237.
29. Zaiss MM, Kurowska-Stolarska M, Böhm C, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol. 2011;186(11):6097-6105.
30. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37(10): 2779-2786.
31. Yang Q, Li G, Zhu Y, et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD81 T cells. Eur J Immunol. 2011; 41(11):3351-3360.
32. Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-51 T cells and promotes allergic-induced airway inflammation independent of IL-4 [published correction appears in J Immunol. 2008;181(11):8170]. J Immunol. 2008;181(7):4780-4790.
33. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23(5):479-490.
34. Guo L, Wei G, Zhu J, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci USA. 2009;106(32):13463-13468.
35. Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA. 2010;107(43): 18581-18586.
36. Dunne A, O'Neill LAJ. The interleukin-1 receptor/ Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2003;2003(171):1-17.
37. Brunner SM, Schiechl G, Falk W, Schlitt HJ, Geissler EK, Fichtner-Feigl S. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int. 2011;24(10):1027-1039.
38. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513(7519):564-568.
39. Enoksson M, Möller-Westerberg C, Wicher G, et al. Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood. 2013;121(3):530-536.
40. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007; 282(36):26369-26380.
41. Nagata A, Takezako N, Tamemoto H, et al. Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells. Cell Mol Immunol. 2012;9(5):399-409.
42. Walzl G, Matthews S, Kendall S, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med. 2001; 193(7):785-792.
43. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun. 2009;386(1): 181-185.
44. Palmer G, Talabot-Ayer D, Lamacchia C, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60(3):738-749.
45. Beltrán CJ, Núñez LE, Díaz-Jiménez D, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(7):1097-1107.
46. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008;205(2):339-346.
47. Jiang H-R, Milovanović M, Allan D, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur J Immunol. 2012;42(7): 1804-1814.
48. Préfontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;183(8):5094-5103.
49. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164(2):277-281.
50. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109(18):2186-2190.
51. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961-2966.
52. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721-726.
53. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001;284(5): 1104-1108.
54. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graftversus-host disease and death. N Engl J Med. 2013;369(6):529-539.
55. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191(6):1069-1076.
56. Leonhardt F, Zirlik K, Buchner M, et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia. 2012;26(7):1617-1629.
57. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol. 2004;173(9):5467-5475.
58. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
59. Takeda K, Tsutsui H, Yoshimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity. 1998;8(3): 383-390.
60. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105(9):1289-1298.
61. Sedhom MAK, Pichery M, Murdoch JR, et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2013;62(12):1714-1723.
62. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209(5):903-911.
63. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graftversus-host disease. Blood. 2009;114(4): 891-900.
64. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin-23 secretion by donor antigen-presenting cells is critical for organspecific pathology in graft-versus-host disease. Blood. 2009;113(10):2352-2362.
65. Das R, Komorowski R, Hessner MJ, et al. Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versusleukemia responses. Blood. 2010;115(25): 5249-5258.
66. Bucher C, Koch L, Vogtenhuber C, et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood. 2009;114(26):5375-5384.
67. Laurence A, Amarnath S, Mariotti J, et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity. 2012;37(2):209-222.
68. Zeiser R, Zambricki EA, Leveson-Gower D, Kambham N, Beilhack A, Negrin RS. Hostderived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(12): 1427-1438.
69. Reddy P, Teshima T, Hildebrandt G, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versusleukemia effects. Blood. 2003;101(7): 2877-2885.
70. Min C-K, Maeda Y, Lowler K, et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD41 and CD81 T-cell subsets after experimental allogeneic bone marrow transplantation. Blood. 2004;104(10):3393-3399.
71. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179(4):2551-2555.
72. Ma H-H, Ziegler J, Li C, et al. Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. Cell Immunol. 2011; 268(1):37-46.
73. Lu SX, Alpdogan O, Lin J, et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood. 2008;112(13):5254-5258.
74. Bonilla WV, Fröhlich A, Senn K, et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science. 2012;335(6071): 984-989.
75. Bourgeois E, Van LP, Samson M, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol. 2009;39(4): 1046-1055.
76. Blom L, Poulsen LK. IL-1 family members IL-18 and IL-33 upregulate the inflammatory potential of differentiated human Th1 and Th2 cultures. J Immunol. 2012;189(9):4331-4337.